Papillex® for abnormal cervical cells caused by HPV

A Randomized, Triple-blind, Placebo-controlled, Parallel Clinical Trial to Investigate the Safety and Efficacy of Papillex® on Abnormal Cervical Cells Caused by HPV

This trial will see if taking Papillex® for 180 days helps abnormal cervical cells caused by HPV improve in women aged 25–55 with CIN 1 or 2.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 60 (estimated)
• Ages: 25 Years to 55 Years
• Sex: Female
• Sponsor: Papillex Inc. (Industry-sponsored)
• Drugs / interventions: chemotherapy, radiation
• Locations: 1 site (London, Ontario)
• Trial ID: NCT06979180 on ClinicalTrials.gov

What this trial studies

This interventional, placebo-controlled trial gives participants either Papillex® or a matching placebo to take for 180 days. The main outcome is the proportion of participants with regression of cervical intraepithelial neoplasia (CIN) on histology or cytology at day 180 compared with baseline. Participants will have Pap smears, HPV testing, questionnaires, and where applicable a colposcopy to document changes. Safety will be monitored through adverse event reporting and scheduled follow-up visits.

Who should consider this trial

Good fit: Women aged 25–55 with a confirmed diagnosis of CIN 1 or CIN 2 who meet the study's contraception or non-childbearing criteria are the intended participants.

Not a fit: People with more advanced disease (for example CIN 3 or invasive cervical cancer), pregnant women, or those unable to follow the 180-day treatment and follow-up plan are unlikely to benefit from this trial.

Why it matters

Potential benefit: If successful, Papillex® could enable non-surgical regression of abnormal cervical cells and reduce the need for invasive procedures.

How similar studies have performed: Previous studies of non-surgical treatments for CIN have shown mixed results, and Papillex® has not yet been established as effective in large trials.

Eligibility criteria

Inclusion Criteria:

1. Females between 25 and 55 years of age
2. Females not of child-bearing potential, defined as those who have undergone a permanent sterilization procedure (e.g. hysterectomy, bilateral oophorectomy or bilateral tubal occlusion) or have been post-menopausal for at least 1 year prior to screening Or,

   Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:
   * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), hormone implant (Norplant System) or intrauterine hormone-releasing system
   * Double-barrier method
   * Intrauterine devices
   * Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)
   * Vasectomized partner, provided that partner is the sole sexual partner and that the vasectomised partner has received medical assessment of the surgical success
   * Abstinence
3. Histologically confirmed CIN1+ (as per standard of care) with concordant hrHPV positivity at that time, and current abnormal cytology and hrHPV positivity at screening; interval between historical diagnosis and screening must be \>12 months OR documented abnormal cytology (LSIL or worse) plus hrHPV positive \>12 months prior, and current abnormal cytology with hrHPV positivity at screening
4. Willing to provide copies of histology and/or cytology reports for eligibility confirmation
5. Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study
6. Willingness to avoid magnetic resonance imaging, computed tomography, X-ray, or other procedures with contrast media injection for 48 hr prior to study visits assessing micronutrient status
7. Willingness and ability to complete questionnaires and diaries associated with the study, and to complete all clinic visits and assessments
8. Provided voluntary, written, informed consent to participate in the study
9. Otherwise healthy as determined by medical history and laboratory results as assessed by Qualified Investigator (QI)

Exclusion Criteria:

1. Women who are pregnant, breast feeding, or planning to become pregnant during the study
2. Allergy, sensitivity, or intolerance preventing consumption of investigational product or placebo ingredients
3. Currently undergoing treatment for CIN, are indicated for treatment during the study period, have received treatment (e.g., conization or loop electrosurgical excision procedure) within the last five years, or have active CIN 3
4. Concurrent uterine pathologies
5. History of hysterectomy or destructive therapy of the cervix
6. Cervical cancer
7. Unstable metabolic disease or chronic diseases as assessed by the QI
8. Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI
9. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI (See Section 7.3)
10. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis
11. History of or current diagnosis with kidney and/or liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months
12. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI
13. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI
14. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable
15. Individuals with an autoimmune disease or are immune compromised
16. Self-reported confirmation of a HIV-, Hepatitis B- and/or C-positive diagnosis as assessed by the QI
17. Self-reported confirmation of blood/bleeding disorders as assessed by the QI
18. Alcohol intake average of \>2 standard drinks per day as assessed by the QI
19. Alcohol or drug abuse within the last 12 months
20. Current use of prescribed and/or over-the-counter (OTC) medications, supplements, and/or consumption of food/drinks that may impact the efficacy and/or safety of the investigational product (Section 7.3)
21. Clinically significant abnormal laboratory results at screening as assessed by the QI
22. Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit
23. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI
24. Individuals who are cognitively impaired and/or who are unable to give informed consent
25. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant

Where this trial is running

London, Ontario

• KGK Science Inc. — London, Ontario, Canada (Recruiting)

Study contacts

• Principal investigator: David Crowley, MD — KGK Science Inc.
• Study coordinator: Erin Lewis, PhD

Conditions CIN - Cervical Intraepithelial Neoplasia; CIN 1; CIN 2; HPV; Cervical Cells; Cervical intraepithelial neoplasia; Papillex